<DOC>
	<DOCNO>NCT02070822</DOCNO>
	<brief_summary>This study prospective clinical study use DCE-MRI , DWI MRS 3T scanner evaluate tumor patient unresectable HCC TACE . A total 100 subject recruit . MRI perform TACE ( day 0 ) , day 14 , day 28 ass tumor response . After day 28 , subject receive standard clinical care follow-up 1 year . The image parameter compare among MRI correlate patient ' outcome . The investigator hypothesis might helpful combine DCE-MRI , DWI , MRS assessment tumor response TACE predict patient ' prognosis .</brief_summary>
	<brief_title>3T MRI Predict TACE Response HCC</brief_title>
	<detailed_description>Dynamic contrast-enhanced magnetic resonance imaging ( DCE-MRI ) non-invasive quantitative technique assess micro-vascular structure track pharmacokinetics inject low-molecular weight contrast agent pass tumor vasculature . This modality increasingly use many oncological study characterize tumor angiogenesis invasiveness , monitor treatment response . Diffusion-weighted imaging ( DWI ) enable qualitative quantitative assessment tissue diffusivity ( apparent diffusion coefficient , ADC ) without use gadolinium chelate . DWI suggest useful monitoring response HCC TACE earlier assessment tumor necrosis increase ADC value . MR spectroscopy facilitates study cellular metabolism vivo detection abnormality . A study vivo MR spectroscopy report increase choline level within tumor HCC reduction lipid-to-choline ratio conventional TACE perform HCC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Prior Informed Consent Form 2 . Patients undergone surgery treatment HCC allow . 3 . At least one measurable tumor , accord RECIST version 1.1 . 4 . Age 20 year . 5 . ECOG performance status 0 1 . 6 . Life expectancy 3 month . 7 . ChildPugh class A . 8 . Unresectable , multinodular tumor 9 . Confirmed Diagnosis HCC 10 . At least one unidimensional lesion measurable accord Modified RECIST criterion MRI 11 . Adequate bone marrow , liver renal function 1 . History TACE 2 . Diffuse infiltrative HCC presence main portal vein invasion extrahepatic metastasis 3 . Any contraindication hepatic embolization procedure : , include hepatofugal blood flow , large intrahepatic portosystemic shunt , impair clot test , renal failure require hemoor peritoneal dialysis 4 . Any contraindication MRI , include know contrast allergy , electronically operate implant device , claustrophobia . 5 . Other acute chronic medical , psychiatric condition , laboratory abnormality may increase risk associate study participation inappropriate study judgment investigator 6 . Known history HIV infection 7 . Concurrent primary extrahepatic cancer 8 . Pregnant breastfeeding subject</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Transarterial chemoembolization</keyword>
	<keyword>Magnetic resonance imaging</keyword>
</DOC>